Click here for slides on this topic


Glycated hemoglobin

Hemoglobin to which a carbohydrate has been attached through a non-enzymatic, time- and concentration-dependent fashion. The fraction of hemoglobin that is glycosylated hemoglobin reflects blood glucose levels during the previous 3 to 4 months. Hemoglobin A1c (A1C) is a form of glycosylated hemoglobin commonly used to assess chronic blood glucose control in people with diabetes. Normal A1C levels are generally 4% to 6%. Diabetes treatment typically aims for a reduction of A1C to a target level of less than 7% to reduce the risk of long-term diabetic complications. The American Diabetes Association recommends a target A1C of less than 7%.


The following content matched the glossary term: Glycated hemoglobin

HARMONY 3: 104-week trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride

Top

Ahrén B, Johnson SL, Stewart M, et al; for the HARMONY 3 Study Group. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. Diabetes Care. 2014;37(8):2141-2148.

Managing the Patient With Type 2 Diabetes and Heart Failure

Top

.style1 FONT FAMILY Arial, Helvetica, sans serif COLOR #004685

Endocrine Society Guideline on Diabetes and Pregnancy - Glycemic Targets & Glucose Management

Top

Diabetes Management Guidelines Endocrine Society Guideline on Diabetes and Pregnancy   Source Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2013 98(11) 4227 4249. Available here.Refer to

T195-04

Top

Patient education handout exploring the connection between diabetes and cardiovascular disease.

Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes

Top

Neugebauer R, Fireman B, Roy JA, O’Connor PJ. Impact of specific glucose-control strategies on microvascular and macrovascular outcomes in 58,000 adults with type 2 diabetes. Diabetes Care. 2013;36:3510-3516.

Glycated hemoglobin measurement and prediction of cardiovascular disease

Top

The Emerging Risk Factors Collaboration. Glycated hemoglobin measurement and prediction of cardiovascular disease. JAMA. 2014;311(12):1225-1233.

ADA 2016 Diabetes Screening and Diagnosis

Top

Criteria for type 2 diabetes diagnosis from the 2016ADA guidelines

Clinical Insights in Diabetes Newsletter October 2013

Top

Clinical Insights® in Diabetes newsletter October 2013

Exploring DPP-4 CV safety in SAVOR-TIMI 53 and EXAMINE, CV outcomes in Look AHEAD, relationship between gastric bypass and A1C and cardiometabolic risk factors, metabolic effects of bariatric surgery and medical therapy in STAMPEDE, statin use and diabetes risk, severe hypoglycemia and CVD disease risk.

1 2 3 4 5 6 7 8 9 10  ... Next 

Slide Library Results

Search Results for: Glycated hemoglobin Slides Found: 12
ACCORD: Results
ADVANCE: Primary Endpoints
ADVANCE Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ADVANCE Trial: Combined Major Macrovascular and Microvascular Events
ADVANCE Trial: Risk for Major Macrovascular and Microvascular Events
ACCORD Trial: Intensive Blood Glucose Control in Patients With Type 2 Diabetes
ACCORD Trial: CV Events With Intensive Blood Glucose Control
Efficacy of Pioglitazone Plus Sibutramine in Metformin-Intolerant vs Metformin-Tolerant Obese Subjects With Type 2 Diabetes
ARIC: Role of A1C in Predicting Hypertension—Design
ARIC: Role of A1C in Predicting Hypertension—Results
A1C CVD Outcomes in Adults Without Diabetes | Diabetes Slides | NDEI
A1C No Benefit CVD Risk Predication in Adults Without Diabetes | NDEI